Hepatocellular carcinoma patients have higher immune tolerance when treated with PD-L1, and PD-L1 blockade does not significantly prolong the survival of hepatocellular carcinoma patients compared with other tumor entities, suggesting that blocking PD-L1 / PD-1 axis alone may not be sufficient to initiate an adequate level of anticancer immunity in hepatocellular carcinoma (35, 36). This evidence concerns the gene CD274 and hepatocellular carcinoma.